Valence 로고
인기
로그인
Loading data for PCVX — first visit, this takes a few seconds.

관심목록에 추가

Vaxcyte Inc.

NasdaqGS: PCVX · 실시간 가격 · USD
63.30
+3.51 (5.87%)
종가 기준: Aug 18, 2026, 3:59 PM
63.67
+0.58%
애프터마켓: 5:08 PM

Vaxcyte Inc. (PCVX) Stock Price, Analysis & Data

5.87%
매수호가45.26
시가총액9.42B
매출 (ttm)n/a
순이익 (ttm)-1.06B
베타1.21
EPS (ttm)-7.63
P/E (ttm)n/a
선행 P/E-8.77
P/B (ttm)3.32
P/S (ttm)n/a
Earnings DateNov 3, 2026
매도호가79.28
거래량1,431,706
평균 거래량 (20일)1,410,637
시가61.56
전일 종가59.79
일중 범위60.95 - 63.79
52주 범위29.87 - 65.00
애널리스트n/a
목표주가n/a
배당n/a
배당락일n/a

PCVX 소개

Vaxcyte, Inc., a clinical-stage vaccine innovation company, develops conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent carrier-sparing investigational pneumococcal conjugate vaccine (PCV) for the prevention of invasive pneumococcal disease (IPD) in infants. The company also develops VAX-31, a 31-valent, carrier-sparing investigational PCV for the prevention of...

[더 보기]
산업 Biotechnology
섹터 Healthcare
IPO 일자 Jun 12, 2020
직원 수 507
상장 거래소 NasdaqGS
티커 PCVX
웹사이트 https://vaxcyte.com
전체 기업 정보

재무 실적

2025년 Vaxcyte의 매출은 0로, 전년 0 대비 undefined% 증가했습니다. 순이익은 -766.63M로, 65.25% 증가했습니다.

재무제표

어닝 서프라이즈

Vaxcyte가 Aug 5, 2026에 분기 실적을 발표했습니다:
  • 매출 $0 예상치 하회 $0, 및 NaN% 전년 대비 성장.
  • EPS -1.97 예상치 상회 0.13, 및 -61.48% 전년 대비 감소.

    • 다음 실적 발표

    Vaxcyte Inc.의 실적 발표 예정일은 Nov 3, 2026, 정규장 중입니다.
    애널리스트 예상 매출은 ... 업그레이드
    news image

    1개월 전 · Insider Monkey

    Vaxcyte Inc (PCVX) Is A Hidden Multibagger Stock To Buy Now

    Vaxcyte Inc. (NASDAQ:PCVX) is one of the 8 Hidden Multibagger Stocks to Buy Now. On June 18, Mizuho Securities analyst Salim Syed reiterated a Buy rating on Vaxcyte Inc. (NASDAQ:PCVX) with a price tar...

    news image

    1개월 전 · Insider Monkey

    Vaxcyte (PCVX) Doses Its First Patient in a Trial for a Disease With No Existing Vaccine

    Vaxcyte, Inc. (NASDAQ:PCVX) is one of the most promising healthcare stocks according to Wall Street analysts. On June 2, Vaxcyte, Inc. (NASDAQ:PCVX) dosed the first participant in its Phase 1 first-in...

    news image

    2개월 전 · Insider Monkey

    Vaxcyte (PCVX) Conducts Initial Dosage for VAX-A1 Phase 1 Study

    Vaxcyte Inc. (NASDAQ:PCVX) is one of the 10 best mid-cap stocks that could double your money. On June 3, Vaxcyte Inc. (NASDAQ:PCVX) announced that the first participant was dosed in the Phase 1, first...

    news image

    2개월 전 · Motley Fool

    Trevi Therapeutics Is Up 100%, Pivotal bioVenture Adds Anyway. Here's Why That Matters.

    This clinical-stage biotech targets chronic pruritus and cough with its lead therapy for neurologically mediated diseases.

    news image

    2개월 전 · Simply Wall St.

    Why Vaxcyte (PCVX) Is Up 8.7% After Completing Key VAX-31 Phase 3 Trial Enrollments

    Vaxcyte recently completed enrollment for three Phase 3 adult clinical trials of its VAX-31 pneumococcal vaccine candidate, along with a Phase 2 VAX-31 infant study, and outlined plans to start a Phas...

    2 페이지 중 1